111, Inc. (YI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY bn | 8 | 12 | 14 | 15 | 14 | 12 | 10 | 18 |
| Operating profit | CNY bn | -0 | -0 | ||||||
| Net profit | CNY bn | -0 | -1 | -0 | -0 | -0 | -0 | -0 | - |
| EPS reported | CNY | -7.42 | -11.92 | ||||||
| Operating cashflow per share | CNY | 13.69 | -9.69 | ||||||
| Capex per share | CNY | 0.51 | 0.51 | ||||||
| FCF per share | CNY | 13.18 | -10.19 | ||||||
| Free cash flow | CNY bn | 0 | -0 | ||||||
| Net debt | CNY bn | -0 | -1 | ||||||
| Book value equity | CNY bn | -1 | -1 | ||||||
| Book value per share | CNY | -80.76 | -87.95 | ||||||
| Number of shares | m | 8.7 | 8.82 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.22 | -0.20 | ||||||
| P/S LTM | x | 0.01 | 0.01 | ||||||
| P/FCF LTM | x | 1.36 | -3.93 | ||||||
| EV/EBITDA LTM | x | -103.85 | 4.62 | ||||||
| EV/Sales LTM | x | -0.02 | 0.02 | ||||||
| Earnings Yield LTM | % | -10.81% | -33.47% | ||||||
| FCF Yield | % | +73.63% | -25.46% | ||||||
| Quality | |||||||||
| ROE | % | +2.40% | +13.93% | ||||||
| ROIC | % | -2.31% | -38.99% | ||||||
| Operating margin | % | -0.08% | -0.24% | ||||||
| Gross margin | % | +5.76% | +5.74% | ||||||
| FCF/Sales | % | +0.94% | -0.79% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -15.19% | -27.48% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -53.72% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.53 | -0.02 | ||||||
| Net Debt/EBITDA | x | -189.82 | 0.54 | ||||||
| EBIT/Net interest | x | -0.29 | -0.78 | ||||||
| Net debt/market cap | % | +1.21% | +16.68% | ||||||
| Net debt/Equity | x | 0.60 | 0.90 | ||||||
| Gross debt/equity | x | -0.31 | -2.46 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free